Hepatocellular carcinoma risk in <scp>HB</scp>eAg‐negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort

Papatheodoridis, George V.; Manolakopoulos, Spilios; Touloumi, Giota; Nikolopoulou, Georgia; Raptopoulou‐Gigi, M.; Gogos, Charalambos; Vafiadis-Zouboulis, Irene; Karamanolis, Dimitrios G.; Chouta, A.; Ilias, A.; Drakoulis, C.; Mimidis, Konstantinos; Ketikoglou, I.; Manesis, Emanuel K.; Mela, Maria; Hatzis, G.; Dalekos, George Ν.

doi:10.1111/jvh.12283

Cited by 41 publications

(45 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using multivariable Cox regression analysis, risk of HCC was independently associated with male gender (P = 0.011), older age (P < 0.001), and cirrhosis (P = 0.025); HCC risk was not associated with the choice of agent used, at least for the first 5 years [36] . In a Taiwanese population-based cohort study, 1,544 patients with active hepatitis due to HBV taking lamivudine, entecavir, tenofovir, or telbivudine over an 8-year period were evaluated for HCC risk and risk of mortality.…”

Section: Impact Of Na Choice On Hcc Incidencementioning

confidence: 99%

The impact of nucleos(t)ide analog therapy in hepatitis B on the incidence of hepatocellular carcinoma: an update including recent literature findings

Ayoub¹,

Dailey²,

Martin³

et al. 2017

View full text Add to dashboard Cite

How to cite this article: Ayoub WS, Dailey F, Martin P, Jones PD. The impact of nucleos(t)ide analog therapy in hepatitis B on the incidence of hepatocellular carcinoma: an update including recent literature findings. Hepatoma Res 2017;3:302-8.Worldwide, hepatocellular carcinoma (HCC) is a significant cause of morbidity and mortality. In men, it is the fifth most common cancer and seventh most common in women; HCC is the second highest cause of cancer-related death worldwide. It is less prevalent in the USA and Northern Europe and more prevalent in Eastern and South-Eastern Asia. Over 700,000 cases are diagnosed each year -half of which occur in China -and result in roughly the same number of deaths per year. HCC significantly impairs quality of life and is associated with great costs to society. It is estimated that half of the deaths from HCC are associated with hepatitis B virus (HBV). Fortunately, HBV vaccination and antiviral therapy have shown excellent efficacy in decreasing the incidence of HCC. We will discuss the relationship of HBV to HCC, address available treatments for HBV and the impact of treatment on the development of HCC. Key words:Liver cancer, hepatocellular carcinoma, hepatitis B, nucleos(t)ides, entecavir; tenofovir, lamivudine ABSTRACTArticle history:

show abstract

Section: Impact Of Na Choice On Hcc Incidencementioning

confidence: 99%

The impact of nucleos(t)ide analog therapy in hepatitis B on the incidence of hepatocellular carcinoma: an update including recent literature findings

Ayoub¹,

Dailey²,

Martin³

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In a recent update of the HEPNET Greece cohort study, the authors compared ETV with LAM, showing a lower HCC incidence (of 0.3%, 1.2%, 2.8% vs 0.7%, 3.8%, 5.6% at 1, 3, and 5 years, respectively; P = 0.024) in the first group. However, in the multivariable Cox regression analysis, the HCC risk was independently associated with older age (P < 0.001), male gender (P = 0.011) and cirrhosis (P = 0.025), but not with the initial antiviral agent [60] . Finally, two recent papers showed that antiviral treatment with ETV did not completely eliminate the risk of developing HCC in patients with cirrhosis [61,62] .…”

Section: Antiviral Therapy and The Risk Of Hccmentioning

confidence: 99%

Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease

Russo

Rodríguez–Castro

Scribano

et al. 2015

WJH

View full text Add to dashboard Cite

interactions among HBV, hepatocytes, and the host immune system. Natural history studies of chronic hepatitis B (CHB) infection have shown an association between active viral replication and adverse clinical outcomes such as cirrhosis and hepatocellular carcinoma. The goal of therapy for CHB is to improve quality of life and survival by preventing progression of the disease to cirrhosis, decompensation, end-stage liver disease, hepatocellular carcinoma (HCC) and death. This goal can be achieved if HBV replication is suppressed in a sustained manner. The accompanying reduction in histological activity of CHB lessens the risk of cirrhosis and of HCC, particularly in non-cirrhotic patients. However, CHB infection cannot be completely eradicated, due to the persistence of covalently closed circular DNA in the nucleus of infected hepatocytes, which may explain HBV reactivation. Moreover, the integration of the HBV genome into the host genome may favour oncogenesis, development of HCC and may also contribute to HBV reactivation. Core tip: The goal of therapy for chronic hepatitis B is to improve quality of life and survival by preventing progression of the disease to cirrhosis, decompensation, end-stage liver disease, hepatocellular carcinoma and death. Current therapeutic options do not eradicate hepatitis B virus (HBV) infection, since HBV remains either integrated in the host genome or in the nuclei of hepatocytes as covalently closed circular DNA, a fact that may favour oncogenesis towards the development of hepatocellular carcinoma, and explains HBV reactivation. It is mandatory for clinicians to start viral suppression in patients with active chronic liver disease, particularly in

show abstract

“…Current guidelines define the goal of therapy for chronic hepatitis B as ‘to improve quality of life and survival by preventing progression of the disease to cirrhosis, decompensated cirrhosis, end-stage liver disease, HCC and death'. Observational studies showed that IFN therapy reduced HBV progression to cirrhosis and decreased HCC incidences in Caucasian and Asian patients [42]. Similarly, nucleos(t)ide analogs suppress viral replication, leading to significantly lower HCC incidence rates in Asian patients compared to historical untreated controls [42].…”

Section: Antiviral Therapy For the Prevention Of Hccmentioning

confidence: 99%

Antiviral Therapy in Patients with Viral Hepatitis and Hepatocellular Carcinoma: Indications and Prognosis

Roderburg¹,

Tacke²

2016

Visc Med

View full text Add to dashboard Cite

Background: Chronic hepatitis B and C infections represent major risk factors for the development of hepatocellular carcinoma (HCC). Recently, the management of patients with viral hepatitis has dramatically changed. In the present review we discuss the impact of these developments on the prevention of HCC as well as the treatment of patients with HCC. Methods: Studies indexed in Medline between 1990 and 2015 (November) were reviewed. The terms ‘hepatocellular carcinoma', ‘HCC', ‘hepatitis B', ‘hepatitis C', ‘viral hepatitis', and combinations of these terms were used. Results: Patients with chronic hepatitis B or hepatitis C without HCC should be evaluated for antiviral therapy, since antiviral therapy was suggested to reduce the risk of HCC development. Cirrhotic patients infected with hepatitis B virus (HBV) require antiviral therapy, while cirrhotics infected with hepatitis C virus (HCV) need to be prioritized for therapy with interferon (IFN)-free regimens. Antiviral therapy should be considered in HBV-infected patients with HCC, especially to prevent tumor recurrence after curative-intended therapy or to prevent hepatic decompensation. HCV-infected patients with HCC should be considered in similar intention for IFN-free antiviral therapy, depending on the tumor stage and life expectancy. Conclusion: Patients with viral hepatitis should be considered for antiviral treatment for the prevention of HCC development as well as during HCC treatment.

show abstract

Hepatocellular carcinoma risk in HBeAg‐negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort

Cited by 41 publications

References 25 publications

The impact of nucleos(t)ide analog therapy in hepatitis B on the incidence of hepatocellular carcinoma: an update including recent literature findings

The impact of nucleos(t)ide analog therapy in hepatitis B on the incidence of hepatocellular carcinoma: an update including recent literature findings

Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease

Antiviral Therapy in Patients with Viral Hepatitis and Hepatocellular Carcinoma: Indications and Prognosis

Contact Info

Product

Resources

About